Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.75 |
| ▸ | ITGAV | P06756 | 20/20 | 0.75 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.75 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838464 | 0.91 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7406088 | 0.88 | ITGB3 (0.65) | ITGB3ITGAVITGA2B | |
| SCHEMBL6016166 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL3368836 | 0.85 | ITGB3 (0.76) | ITGB3ITGAVITGA2B | |
| SCHEMBL7138885 | 0.85 | ITGB3 (0.76) | ITGB3ITGAVITGA2B | |
| SCHEMBL7216195 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7217041 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6832958 | 0.82 | ITGB3 (0.68) | ITGB3ITGAVITGA2B | |
| SCHEMBL7919745 | 0.82 | ITGB3 (0.70) | ITGB3ITGAVITGA2B | |
| SCHEMBL6832483 | 0.81 | ITGB3 (0.72) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010018458-A2 | PHENOL DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2010-02-18 | — | — | WO | claimed |
| US-6492356-B1 | Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-10 | — | — | US | claimed |
| EP-1042301-B1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2002-11-20 | — | — | EP | claimed |
| EP-1042301-A1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| EP-0933367-A1 | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-08-04 | — | — | EP | claimed |
| WO-1999032457-A1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-01 | — | — | WO | claimed |
| EP-1326847-B1 | (2S)-2-(ADAMANTAN-1-YLMETHOXYCARBONYLAMINO)-3-(4-(2-(1,4,5,6-TETRAHYDROPYRIMIDIN-2-YLCARBAMOYL)ETHYL)BENZOYLAMINO)PROPIONIC ACID ISOPROPYL ESTER, ITS PREPARATION AND ITS USE | AVENTIS PHARMA GMBH (DE) | 2010-05-05 | — | — | EP | disclosed |
| WO-2010018458-A2 | PHENOL DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2010-02-18 | — | — | WO | disclosed |
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
| EP-0820991-B1 | Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists | HOECHST AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-6867213-B2 | (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20040039006-A1 | (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
| US-6399620-B1 | (2S)-2-(1-ADAMANTYL-METHYLOXYCARBONYLAMINO)-3-(4-(3-GUANIDINO -CARBONYL-PROPYLOXY)PHENYL)PROPIONIC ACID; ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA S.A. (DE) | 2002-06-04 | — | — | US | disclosed |
| WO-2002030910-A1 | (2S)-2-(ADAMANTAN-1-YLMETHOXYCARBONYLAMINO)-3-(4-(2-(1,4,5,6-TETRAHYDROPYRIMIDIN-2-YLCARBAMOYL)ETHYL)BENZOYLAMINO)PROPIONIC ACID ISOPROPYL ESTER, ITS PREPARATION AND ITS USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-18 | — | — | WO | disclosed |
| EP-1197488-A1 | (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use | Aventis Pharma Deutschland GmbH (DE) | 2002-04-17 | — | — | EP | disclosed |
| EP-1042301-A1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| EP-0933367-A1 | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-08-04 | — | — | EP | disclosed |
| WO-1999032457-A1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-01 | — | — | WO | disclosed |
| EP-0820991-A2 | Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039006-A1 | (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use | CALCRL, CALCR, CHRNA1 | ITGB3 153/4885ITGAV 223/4885ITGA2B 101/4885 |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | ITGB3 536/4885ITGAV 737/4885ITGA2B 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.